Sanofi･aventis：製藥企業分析報告 是由出版商Espicom Business Intelligence在2007年09月所出版的。
這份英文市場調查報告書包含Pages: 212 價格從美金1040起跳。
Abstract
sanofi-aventis ranks third amongst research-based pharmaceutical companies,
behind Pfizer and GlaxoSmithKline. This report provides a full review of the
company's activities together with sales forecasts for key products to 2010.
sanofi-aventis was formed in August 2004, when Sanofi-Synthélabo
acquired control of Aventis. Subsequently, on 31st December 2004, Aventis
merged with and into sanofi-aventis, with sanofi-aventis as the surviving
company. With total revenues of over EUR 27 billion in 2005, the combined
entity ranks third amongst research-based pharmaceutical companies behind
Pfizer and GlaxoSmithKline.
sanofi-aventis is focused on two core areas, pharmaceuticals (principally
prescription drugs) and human vaccines. Within the pharmaceutical area,
sanofi-aventis is active in the following therapeutic areas:
Cardiovascular/Thrombosis, Metabolism, Oncology, Central Nervous System and
Internal Medicine (which includes Respiratory/Allergy, Urology,
Arthritis/Osteoporosis and Anti-infectives).
Current Growth Drivers
In the cardiovascular field, Plavix is sanofi-aventis' second best selling
product and has demonstrated strong year-on-year sales increases. The recent
approval in Japan for the treatment of stroke (January 2006) will further
boost sales and is expected to expand sanofi-avenits' profile within this
market.
Lantus has achieved remarkable year-on-year growth in an increasingly
competitive field, with its once-daily dosing setting it apart from its
competitors. The US launch of Lantus in combination with Apidra, scheduled for
the first quarter of 2006, is anticipated to further bolster sales, allowing
it to make significant gains in the metabolic market.
Sales of Actonel for use in the prevention and treatment of postmenopausal
osteoporosis and corticosteroid-induced osteoporosis, are showing a steady
increase. Estimated peak sales of this product are forecast at over US$1
billion.
sanofi pasteur (sanofi-aventis' vaccines subsidiary) is a world leader in the
development and marketing of vaccines. 2005 saw three successful launches:
Decavac, Menactra and Adacel. sanofi pasteur also has the ability to exploit
the expanding influenza market. The following launches are set to drive growth
in 2006: Pediacel (polio, pertussis/Hib)' ProQuad (measles, mumps, Rubella and
Varicella); Gardasil (Herpes and genital infections); RotaTeq (rotavirus
infections); Zostavax (Zoster) and Menactra (meningitis).
Table of Contents
Principal Operating Results Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Future Growth Drivers
- Financial Performance 2005
- Sales and Market Position
- Income
- Sales, Costs and Operating Income, 2005
- Operating Income By Business Area
- Operating Income By Geographical Area
- Expenditure
- Restructuring Costs
- Other Expenses
- Capital Expenditure
- Capital Expenditure By Geographic Area
- Capital Expenditure By Geographic Area, 2005
- R&D Expenditure
- R&D Expenditure By Business Area
- R&D Expenditure By Business Area, 2005
- Divisional Performance
- Sales By Business Area
- Sales By Business Area, 2005
- Total Human Vaccine Sales
- Breakdown of Vaccine Sales, 2005
- Geographic Performance
- Total Net Sales By Geographic Area
- Total Net Sales By Geographic Area, 2005
- Total Assets By Geographic Area
- Product Sales By Geographical Region
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Mergers
- Acquisitions
- Divestitures
- Key Agreements
- Production
- Employees
- Consolidated Employees By Geographic Area
- Employees By Geographic Area, 2005
- Consolidated Employees By Main Category Of Function
- Consolidated Employees By Function, 2005
- Product / R&D Overview
- Vaccines
- Key Products
- Recent Product Launches
- Discontinued Products
- R&D Strategy
- R&D Pipeline Overview
- Discontinued R&D Projects
- Cariporide (HOE 642)
- Dynepo (HMR 4396)
- SL 25.1039
- SR 49059
- SR 27897
- Sales Forecasts
- Sales of Current Top Ten Products (2000A-2010E)
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- Top Selling Products, 2005
- R&D Pipeline
- Cardiovascular / Thrombosis - Products
- Major Launched Products
- Aviator/Aprovel/Avapro/Avalide/CoAprovel
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Aprovel sales (2000A-2010E)
- Delix/Tritace/Triatec
- Sales
- Key Markets/Indications.Formulations
- Patents
- Competitor Products
- Sales Forecast
- Delix sales (2000A-2010E)
- Lovenox/Clexane
- Sales
- Key Markets/Indications/Formulations
- Further development
- Patents/Generic Competition/Lawsuits
- Competitor Products
- Sales Forecasts
- Lovenox Sales (2000A-2010E)
- Plavix/Iscover
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Further Development
- Patents
- Lawsuits - Aircoat
- Lawsuits - Apotex and Ranbaxy
- Safety Issues
- Sales Forecast
- Plavix sales (2000A-2010E)
- Cardiovascular / Thrombosis - R&D
- Ataciguat (HMR1766)
- AVE0118
- AVE1231
- AVE3247
- AVE7688
- AVE9488
- Dronedarone
- HMR1069
- Idraparinux
- Octaparine (AVE5026)
- Otamixaban (XRP0673)
- SL 65.0472
- SR 123781
- SSR 126517
- SSR 149744
- XRP0038 (NV1FGF)
- Cardiovascular / Thrombosis - Summary
- Growth Potential
- Limiting Factors
- Oncology - Products
- Eloxatin
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits
- Competitor Products
- Sales Forecast
- Eloxatin sales (2000A-2010E)
- Fasturtec/Elitek
- Key Markets/Indications/Formulations
- Further Development
- Taxotere
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents
- Competitor Products
- Sales Forecast
- Taxotere sales (2000A-2010E)
- Oncology - R&D
- Alvocidib
- AVE 0005
- Studies with Regeneron
- Clinical Trial Results
- AVE 8062
- AVE9633
- CEP7055
- SR 31747/SSR 125329
- Tirazone
- Uvidem
- XRP6258
- XRP9881
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Central Nervous System - Products
- Major Launched Products
- Copaxone
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Copaxone Sales (2000A-2010E)
- Depakine
- Sales
- Key Markets/Indications/Formulations
- Sales Forecast
- Depakine Sales (2000A-2010E)
- Stilnox/Stilnoct/Ambien/Myslee
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits/Generic Competition
- Safety Issues
- Competitor Products
- Sales Forecast
- Stilnox Sales (2000A-2010E)
- Central Nervous System - R&D
- Acomplia
- AVE1625
- AVE9897
- Eplivanserin (SR 46349)
- HP184
- M100907
- Saredutant (SR 48968)
- SR 57667
- SR 58611
- SSR 125543
- SSR 149415
- SSR 180575
- SSR 411298
- SSR 504734
- SSR 591813
- Teriflunomide
- Xaliproden (SR 57746)
- Central Nervous System - Summary
- Growth Potential
- Limiting Factors
- Metabolism / Diabetes - Products
- Major Launched Products
- Apidra
- Further Development
- Clinical Trial Results
- Amaryl
- Sales
- Sales Forecast
- Key Markets/Indications/Formulations
- Generic Competition
- Competitor Products
- Sales Forecast
- Amaryl Sales (2000A-2010E)
- Lantus
- Sales
- Key Markets/Indications
- Patents
- Further Development
- Patents/Lawsuits/Generic Competition
- Competitor Products
- Sales Forecast
- Lantus sales (2000A-2010E)
- Metabolism / Diabetes - R&D
- AVE0010 (ZP10)
- AVE0847
- AVE2268
- AVE5530
- AVE5376
- AVE8134
- SSR 162369
- Metabolism / Diabetes - Summary
- Growth Potential
- Limiting Factors
- Vaccines - Products
- Vaccine Sales by Area
- Vaccine Sales, 2005
- Influenza
- Sales
- Key Products
- Further Development
- Polio/Whooping Cough/HIB
- Sales
- Key Products
- Further Development
- Adult booster
- Meningitis
- Sales
- Key Products
- Further Development
- Safety Issues
- Clinical Trial Results
- Travel Vaccines
- Sales
- Further Development
- Vaccines - R&D
- Cytomegalovirus
- Dengue Fever Vaccine
- Flu Infants
- Flu Micro-Injection
- Flu Pandemia
- Gardasil
- HIV/AIDS Vaccines
- HR51
- Zostavax
- Vaccines - Summary
- Growth Potential
- Limiting Factors
- Respiratory / Allergy - Products
- Major Launched Products
- Allegra/Telfast
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents/Lawsuits/Generic Competition
- Sales Forecast
- Allegra Sales (2000A-2010E)
- Alvesco
- Key Markets/Indications/Formulations
- Further Development
- Clinical Trial Results
- Nasacort/Nasacort AQ/Nasacort HFA
- Sales
- Key Markets/Indications/Formulations
- Sales Forecast
- Nasacort Sales (2000A-2010E)
- Respiratory / Allergy - R&D
- Arthritis / Osteoporosis - Products
- Major Launched Products
- Actonel
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Generic Competition/Lawsuits
- Clinical Trial Results
- Competitor Products
- Sales Forecast
- Actonel Sales (2000A-2010E)
- Arthritis / Osteoporosis - R&D
- Genito-urinary - Products
- Major Launched Products
- Xatral
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Genito-urinary - R&D
- Anti-infective - Products
- Ketek
- Key Markets/Indications/Formulations
- Further Development
- Safety Issues
- Anti-infective - R&D
- Ferroquine (SSR 97193)
- Picovir
- XRP2868
- Other - Products
- Other - R&D
- SR 121463
- SSR 126768
- SSR 150106
- SSR 240612
- Internal Medicine - Summary
APPENDIX 1 - FINANCIAL PERFORMANCE
- Full Year Results 2005
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREEMENTS
- aaiPharma
- Acambis plc
- 28th April 1998
- 11th May 1999
- Ajinomoto Co Inc
- Altana Pharma AG
- 15th October 1999
- 26th March 2001
- Amgen
- Astellas Pharma Inc
- 12th July 1999
- 14th November 2001
- 19th April 2002
- 13th February 2003
- 20th November 2003
- 16th December 2005
- 12th April 2006
- Astex Technology
- 25th March 2002
- 8th June 2004
- AstraZeneca
- Atrix Laboratories Inc
- 9th January 2001
- 16th March 2004
- Becton Dickinson and Company (BD)
- 12th April 1999
- 21st December 2005
- Bristol-Myers Squibb
- 8th June 2001
- 21st March 2006
- Celera Genomics/Axys Pharmaceuticals
- Cephalon Inc
- 20th December 2001
- 8th January 2002
- Chiron Corporation
- Ciphergen Biosystems
- Coley Pharmaceutical Group Inc
- Crucell NV
- 24th January 2003
- 7th January 2004
- Daiichi Sankyo
- July 1993
- 13th February 2003
- 5th July 2005
- Dainippon Sumitomo Pharma
- Debiopharm SA
- Eli Lilly
- French Ministry of Health
- GlaxoSmithKline
- 12th February 1998
- 23rd September 1998
- IDM Pharma Inc
- 22nd January 2002
- 19th February 2002
- 4th December 2002
- ImmunoGen Inc
- 31st July 2003
- 31st August 2005
- King Pharmaceuticals Inc
- 22nd December 1998
- 31st December 2002
- Millennium Pharmaceuticals Inc
- 13th August 2001
- Inflammation agreement
- Technology development agreement
- Technology transfer agreement
- Nabi Biopharmaceuticals
- Novo Nordisk
- Pfizer
- 26th January 2001
- 14th October 2002
- 1st March 2006
- Prasco Laboratories
- Procter & Gamble
- 5th May 1997
- 8th October 2004
- Regeneron Pharmaceuticals Inc
- 10th January 2005
- 22nd December 2005
- Roche/Genentech
- 6th December 2000
- 16th March 2006
- SAS Institute
- Shionogi
- Teva Pharmaceutical Industries Ltd
- September 1993
- 14th February 2001
- US Government
- April 2005
- September 2005
- VaxGen Inc
- Zealand Pharmaceuticals A/S
- Licensing
- Co-Promotion/Co-Marketing
APPENDIX 4 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Major Fully-Consolidated Subsidiaries
- Major Associates
- Joint Ventures
APPENDIX 6 - PRODUCT INDEX
